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Background: Based on global gene expression profile, therapeutic effects of Qishenyiqi
(QSYQ) on acute myocardial infarction (AMI) were investigated by integrated analysis at
multiple levels including gene expression, pathways involved and functional group.
Methods: Sprague-Dawley (SD) rats were randomly divided into 3 groups:
Sham-operated, AMI model (left anterior descending coronary artery ligation) and
QSYQ-treated group. Cardiac tissues were obtained for analysing digital gene
expression. Sequencing and transcriptome analyses were performed collaboratively,
including analyses of differential gene expression, gene co-expression network, targeted
attack on network and functional grouping. In this study, a new strategy known as
keystone gene-based group significance analysis was also developed.
Results: Analysis of top keystone QSYQ-regulated genes indicated that QSYQ
ameliorated ventricular remodeling (VR), which is an irreversible process in the
pathophysiology of AMI. At pathway level, both well-known cardiovascular diseases
and cardiac signaling pathways were enriched. The most remarkable finding was
the novel therapeutic effects identified from functional group analysis. This included
anti-inflammatory effects mediated via suppression of arachidonic acid lipoxygenase
(LOX) pathway and elevation of nitric oxide (NO); and amelioration of dyslipidaemia
mediated via fatty acid oxidation. The regulatory patterns of QSYQ on key genes were
confirmed by western blot, immunohistochemistry analysis and measurement of plasma
lipids, which further validated the therapeutic effects of QSYQ proposed in this study.
Conclusions: QSYQ exerts multipronged therapeutic effects on AMI, by concurrently
alleviating VR progression, attenuating inflammation induced by arachidonic acid LOX
pathway and NO production; and ameliorating dyslipidaemia.
Keywords: Acute myocardial infarction, Qishenyiqi, anti-inflammation, dyslipidaemia, group significance analysis
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INTRODUCTION
Acute myocardial infarction (AMI) is the most frequent cause
of heart failure (HF) (Mahmood et al., 2014; Maranhão
and Tavares, 2015). Although evidence-based therapies have
been established, AMI-induced HF remains a leading cause
of global mortality (Gaziano et al., 2006). Herbal formulas
of traditional Chinese medicine (TCM) have been effectively
used in treatment of AMI with few side-effects (Ferreira and
Lopes, 2011). One of the commonly used TCM for AMI
is Qishenyiqi (QSYQ). QSYQ originates from the recordings
of classic medical textbook, “Treatise on Exogenous Febrile
Disease.” It has been effectively used in treatment of several
diseases for thousands of years. It is prepared from 6 herbs,
including 2 star herbs: Astragalus membranaceus (Fisch.) Bunge
(“huang-qi” in Chinese) and Salvia Miltiorrhiza Bunge (“dan-
shen” in Chinese), and 4 adjunctive herbs: Lonicera japonica
Thunb., Scrophularia aestivalis Griseb., Aconitum fischeri Rchb.,
and Glycyrrhiza uralensis Fisch.
Clinical studies and preclinical researches in human and
animal models have shown the positive effects of QSYQ on the
ejection fraction as well as hemodynamics in AMI (Wang et al.,
2012a,b, 2013; Li et al., 2014; Luo et al., 2014). Recently, extensive
efforts have beenmade to investigate the mechanisms of action of
QSYQ in the treatment of AMI. Studies on animal models have
shown that QSYQ improves ligation-induced left ventricular
remodeling (VR), by attenuating inflammation and fibrosis.
This is mediated via interleukin 6 (IL-6)—signal transducer and
activator of transcription 3 (STAT3) and tumor necrosis factor α
(TNFα)—nuclear factor kappa-light-chain-enhancer of activated
B cells (NFκB) signaling pathway, and this leads to decreased
concentrations of transforming growth factor β (TGF-β) and
matrix metallopeptidase 9 (MMP-9) (Li et al., 2014). Wang
et al. (2012b) predicted potential drug targets of QSYQ using
bioinformatics. They also performed experiments to validate
the effects of QSYQ on these predicted targets on an animal
model. One of the possible target is the inhibition of Renin-
angiotensin-aldosterone system (RAAS) pathway, including
renin, angiotensin II type 1 receptor (AT1), angiotensin II
Abbreviations: AMI, Acute myocardial infarction; HF, Heart failure; TCM,
Traditional Chinese medicine; QSYQ, Qishenyiqi; IHC, Immunohistochemistry;
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LVIDs, Left ventricular internal diameter at end-systole; EF, Ejection fraction; FS,
Fractional shortening; LV, Left ventricular; GCN, Gene co-expression network;
FDR, False discovery rate; ES, Enrichment score; TC, Total cholesterol; TG,
Triglyceride; HDL, High density lipoprotein; LDL, Low density lipoprotein;
ECM, Extracellular matrix; AA, Arachidonic acid; LOX, Lipoxygenase; ALOX15,
Arachidonate 15-lipoxygenase; ALOX5, Arachidonate 5-lipoxygenase; 15-HPETE,
15-Hydroxyeicosatetraenoic acid; MMP, Matrix metalloproteinase; MMP-2,
Matrix metallopeptidase 2; MMP-23, Matrix metallopeptidase 23; VR, Ventricular
remodeling; ALOX5AP, Arachidonate 5-lipoxygenase activating protein; NO,
Nitric oxide; NOS3, Nitric oxide synthase 3; CD36, Cluster of differentiation
36; ACSL1, Acyl-CoA synthetase long-chain family member 1; CPT2, Carnitine
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type 2 receptor (AT2), and angiotensin converting enzyme 2
(ACE2) (Wang et al., 2012a). Furthermore, as downstream
molecules of RAAS pathway, different subtypes of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase (NOX) in
oxidative stress are also regulated by QSYQ in different patterns.
Specific pathways including angiotensin II (AngII)—NADPH
oxidase 2 (NOX2)—reactive oxygen species (ROS)—matrix
metallopeptidases (MMPs) and angiotensin II (AngII)—NADPH
oxidase 4 (NOX4)—reactive oxygen species (ROS)—matrix
metallopeptidases (MMPs) are also regulated by QSYQ and
contribute to the reduction of apoptosis in p53 and caspase-
3 pathways (Wang et al., 2013). In addition, components
of QSYQ also exert effects on lipid metabolism, including
down-regulating plasma ox-low density lipoprotein (ox-LDL)
and low density lipoprotein (LDL) levels (Yong et al., 2012).
Collectively, these studies demonstrate diverse therapeutic effects
of QSYQ on AMI-induced HF, including anti-inflammation,
anti-fibrosis, anti-apoptosis, inhibition of RAAS activation and
lipid metabolism disorder, which eventually lead to restoration of
normal hemodynamic parameters and cardiac function.
Previous studies indicated that QSYQ exerts its therapeutic
effects on AMI through different target pathways in a synergistic
manner (Wang et al., 2012a,b, 2013; Qiu et al., 2014). However,
the major limitation of these studies is that the effects of QSYQ
on different pathways were not examined simultaneously. TCM
is an ancient medical practice system which emphasizes the
integrity of entire human body and it usually exerts therapeutic
effects via multiple targets or pathways (Qiu et al., 2014).
However, determination of multiple complex pathways and their
interactions remains a challenge for TCM research. In recent
years, multiple high-throughput omics technologies, including
transcriptomics, proteomics, metabolomics and metagenomics,
have been increasingly applied in TCM research (Gu and
Chen, 2014). To meet the development and application of
omics technologies in TCM research, routine bioinformatics
strategies, which focus on differentially expressed genes (DEGs)
and enriched pathways, have been evolved into advanced
stages, which need to integrate multiple omics data, and
more advanced network-based methods to identify hub genes
and functional groups regulated by drug intervention (Berg,
2014). In our study, we obtained a well characterized high-
throughput RNA sequencing expression profile (Zhu et al.,
2011), complemented by Western blot, immunohistochemistry
(IHC) and measurement of plasma lipids, to identify global
gene expression changes induced by QSYQ treatment on AMI.
We also developed a new strategy to analyse the significance
of functional group based on the priorities of keystone genes,
to better understand the molecular mechanisms of these gene
expression changes.
MATERIALS AND METHODS
Experimental Animals
Studies were performed according to the “Guide for the Care
and Use of Laboratory Animals” published by National Institutes
of Health (NIH Publications No. 85-23, revised 1996) and with
approval of the Animal Care Committee of Beijing University of
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Chinese Medicine. A total of 45 male Sprague-Dawley (SD) rats
with weights of 240± 10 g in Specific Pathogen Free (SPF) grade
were selected (purchased from Beijing Vital River Laboratory
Animal Technology Co. Ltd.).
Model Preparation of AMI and Grouping
Total 45 rats were randomly divided into 3 groups (15 rats
per group): Sham-operated, AMI model and QSYQ-treated
group. Rats in AMI model and QSYQ-treated groups received
ligation surgery of left anterior descending (LAD) coronary
artery (Wang et al., 2012b). Left thoracotomy between third
and fourth intercostal space was performed on rats. After
exposing the cardiac tissues, LAD was ligated with a sterile
suture (Shuangjian, Shanghai, P.R. China) 1 mm below the
left atrium. The thorax was then closed layer by layer. After
thoracotomy, rats were warmed on a heated blanket. One day
after the surgery, rats in QSYQ-treated group received a dosage
of 2.33 g/kg concentrated QSYQ via oral gavage. QSYQ is a
combination of six Chinese herbs that includes A. membranaceus
(Fisch.) Bunge, S. Miltiorrhiza Bunge, L. japonica Thunb., S.
aestivalis Griseb., A. fischeri Rchb. and G. uralensis Fisch. in
the ratios of 10:5:3:3:3:2 (Wang et al., 2012b). It was derived by
mixing the residue of A. membranaceus (Fisch.) Bunge with all
S. Miltiorrhiza Bunge, L. japonica Thunb., S. aestivalis Griseb.,
A. fischeri Rchb. and G. uralensis Fisch., followed by extraction
with hot water (twice, 2 h each). The water extract was then
concentrated to form a paste, and the ethanol is added. After
24 h, the filtration is collected to form the final product (Wang
et al., 2012b). Quality of QSYQ was evaluated and established
by its fingerprints with HPLC-IT-TOF method (shown in Figure
S1). The dosage is ideal to exert definite effect for QSYQ on AMI
rat model according to our previous study (Li et al., 2014). Rats
in AMI model group were only treated with the same volume
of water as QSYQ-treated group (Wang et al., 2012a). Rats in
Sham-operated group underwent the same procedure like AMI
model rats but had no actual ligation of LAD. The mortality
rate of surgery was 26.7%. After surgery, there were 2, 6, and
4 rats which died inadvertently in Sham-operated, AMI model
and QSYQ-treated groups respectively. Most of these rats died
on the day of surgery or the following day, likely due to acute
pump failure or lethal arrhythmias. After 28 days, eight rats
from each group were assessed by echocardiography following
overnight fasting. The cardiac tissues of all rats were harvested
for subsequent molecular biology experiment (13, 9, and 11
rats in Sham-operated, AMI model, and QSYQ-treated groups
respectively). Among them, 9 rats were selected randomly for
digital gene expression sequencing (3 rats per group). Total RNA
of cardiac tissues was extracted with TRIzol Reagent (Gibco-
BRL, Paisley, UK). The concentration of RNAwas measured with
Nano Drop 2000 (Thermo Scientific, USA).
Echocardiographic Assessment of Left
Ventricular (LV) Function
The high-frequency, high-resolution digital imaging platform
from the Vevo 2100 system (VisualSonics Inc., Canada) was
applied to generate 2D M-mode and B-mode echocardiography.
After 28 days of QSYQ treatment and before harvesting
the cardiac tissues, 8 rats in each group were assessed by
echocardiography. The independent operator was from scientific
center of Beijing University of Chinese Medicine. LV internal
diameter at end-diastole (LVIDd), LV internal diameter at end-
systole (LVIDs), ejection fraction (EF) and fractional shortening
(FS) were detected by echocardiography (Sharrett et al., 2001;
Wang et al., 2015).
Hemodynamic Measurements in Rats
LV performance was measured in rats after they were
anesthetized with 2% isoflurane as described earlier (Li et al.,
2014). A terminal hemodynamic study was performed 28 days
after surgery. Nine rats were included in each group. Right
carotid artery, LV systolic and end-diastolic, diastolic and mean
aortic pressures, Max dP/dt, Min dP/dt, and heart rate were
recorded with a system of PowerLab ML880 (AD Instrument,
Australia).
DGE-Tag Gene Expression Profiling
Cardiac tissues of ischemic marginal zone were collected after
28 days of QSYQ treatment as described above. After extracting
from cardiac tissues, mRNA was purified and reverse transcribed
into cDNA with Oligo (dT) magnetic beads. The cDNA
was then digested with 2 endonucleases (NlaIII and MmeI)
and ligated with adaptors. After linear PCR amplification of
cDNA, the library of each sample was sequenced with Illumina
HiSeqTM 2000. Dirty tags were filtered out. All clean tags were
aligned to rat reference sequences and unambiguous tags were
annotated. The number of clean tags belonging to each gene
was computed as raw gene expression count, which could be
normalized to the total number of transcripts in each sample
per million clean tags (TPM normalization). Finally, a well-
characterized transcriptome profile of total 10,515 mRNAs was
established.
Gene Co-expression Network (GCN)
Analysis
Pearson’s correlation coefficient was used as co-expression
measure for constructing GCN. For a given coefficient of a gene
pair, Student asymptotic p-value was calculated and then adjusted
with false discovery rate (FDR). GCN consists of gene pairs with
FDR < 0.05.
PageRank centrality (Brin and Page, 2012) is an indicator
to identify “hub genes” in GCN. It is the extension of degree
centrality, which indicates significance of nodes in a network.
PageRank, together with targeted attack on network analysis
(Achard et al., 2006), was used to identify keystone QSYQ-
regulated genes.
Keystone Gene-Based Group Significance
Analysis
Since the enriched KEGG pathways have close linkages between
each other in KEGGmap, we merged them to form a background
network, using KEGGgraph R package. From this network, all
QSYQ-responsive genes (DEGs of comparison between QSYQ-
treated and AMI model groups) were extracted to form a sub-
network. Functional groups were divided from the sub-network
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using “leading eigenvector” method (Newman, 2006) with igraph
R package. A new strategy was further developed to calculate
enrichment degrees of functional groups with keystone QSYQ-
regulated genes, and estimate significance levels. There are 3 key
steps in this strategy.
Step 1: Generation of Priority List for Keystone
QSYQ-Regulated Genes
PageRank scores in GCN were scaled in the range of 0–1.
The minimum of PageRank scores was subtracted from each
PageRank score. Each PageRank score was then divided by the
range of PageRank scores. A priority list L consists of scaled
PageRank scores of keystone QSYQ-regulated genes in sub-
network. Genes in list L were prioritized in decreasing order of
scaled PageRank scores.
Step 2: Calculation of Enrichment Score (ES) for Each
Functional Group
We calculated ES that reflects the degree to which a functional
group C is overrepresented at the top of priority list L. Given
the list L, ES was calculated by walking down list L. During the
walking, when we encounter a gene in group C, we increase a
running-sum statistic (hits score “Phit”); when we encounter a
gene not in group C, we decrease it (penalty score “Pmiss”). “Phit”
and “Pmiss” were calculated as formulas (1) and (2), respectively.
In the formula (1), sj represents scaled PageRank score of gene gj.
In the formula (2), Ndiff means the count of genes in difference
set between group C and list L; Ngenelist and Ngroup denote the
count of genes in list L and group C, respectively.
Phit(C, i) =
∑
gi∈C
j≤ i
Sj (1)
Pmiss(C, i) =
∑
gj /∈C
j≤ i
Ndiff
Ngenelist × Ngroup
(2)
Finally, ES is the maximum of Phit-Pmiss. If genes in a group C are
randomly distributed across list L, or distributed at the bottom
of list L, ES(C) will be relatively low or even negative. On the
contrary, if they are concentrated at the top of list L, ES(C) will be
high. In our strategy, both count (Pmiss) and significance degree
(Phit) of keystone genes were taken into considerations.
Step 3: Estimation of Significance Level of ES by
Monte Carlo Simulation
For a functional group C, the statistical significance (nominal P
value) of ES was estimated over a null distribution, which was
generated from 10,000 times of Monte Calro simulations. The
main steps are as follows:
(a) Randomly sample NC genes from the background network
to form a group Crandom and re-compute ESrandom. NC is the
count of genes in group C,
(b) Repeat step (a) for 10,000 times, and create a null distribution
of enrichment scores ESNULL,
(c) Estimate nominal P value for ES of group C from ESNULL
with the positive portion, that is P(C) = #(ESNULL ≥
observed ES)/10,000, which #(ESNULL ≥ observedES)
represents the count of ESNULL that is larger than the ES of
group C.
The estimated significance levels (P-values) of all the functional
groups were adjusted for multiple hypothesis testing with Simes-
Hochberg method (Jacquez, 1996).
Experimental Validation with Western Blot,
IHC and Measurement of Plasma Lipids
(TC, TG, HDL, and LDL)
Cardiac tissues were lysed and homogenized using RIPA buffer
(Applygen Technologies Inc., Beijing, China). Total protein
was extracted from the tissue homogenate. Concentration
in each sample was detected by BCA assay kit (Applygen
Technologies Inc., Beijing, China). Equal amounts of protein
were separated with SDS-PAGE and transferred onto NC
membranes (Applygen Technologies Inc., Beijing, China).
The following primary antibodies were used: MMP-2(1:500
dilution; Abcam, Cambridge, UK), NOS3(1:2,500 dilution;
BD Transduction Laboratories, US), ALOX15(1:1,000
dilution; Abcam, Cambridge, UK), CPT2(1:1,000 dilution;
Abcam, Cambridge, UK), CD36(1:1000 dilution; Abcam,
Cambridge, UK), LPL(1:500 dilution; Abcam, Cambridge, UK),
BCKDHA(1:1,000 dilution; Abcam, Cambridge, UK), DBT(1:500
dilution; Abcam, Cambridge, UK), GAPDH(1:10,000 dilution;
Abcam, Cambridge, UK). Three rats in each group were detected
for 3 biological replicates.
IHC was performed with cell & tissue staining kits (R&D
Systems, Inc., USA) and followed by the protocol (Li et al., 2014).
6 rats in each group were incubated with primary antibody (1:200
dilution; Anti-Collagen III antibody, Abcam, Cambridge, UK;
1:200 dilution; Anti-Collagen V antibody, Abcam, Cambridge,
UK) for 12 h. 5 visual fields were selected for each sample
and analyzed with Image-Pro Plus 6.0 software to determine
the integrated optical density (IOD) in the positive stained
areas.
Twenty-eight days after surgery, animals were sacrificed
after anaesthetization and blood was taken through
abdominal aorta. The blood was centrifuged at 8,000 g for
10 min and supernatant was used for detection of plasma
indicators. Six rats were included in each group. Plasma
levels of total cholesterol (TC), triglyceride (TG), high
density lipoprotein (HDL) and low density lipoprotein
(LDL) were measured by automatic biochemical analyzer
(HITACH17080, Japan). Plasma levels were quantified by
comparing with standards of TC, TG, HDL, and LDL from
Sekisui chemical Diagnostic reagents (Sekisui chemical co., LTD,
Japan).
Statistical Analysis
DEGs were detected by DESeq2 R package, with FDR <
0.10 (for reference of Love et al., 2014) and absolute value
of log2 fold change >0.58. KEGG enrichment analysis
was performed using “clusterProfiler” R package with P <
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0.05. In experimental validation, all data were presented
as mean ± standard deviation. Statistical analysis was
carried out on one-way analysis of variance (ANOVA)
and Dunnetts’ test. P < 0.05 were considered statistically
significant. Statistical analysis was performed in R 3.1.3
software.
RESULTS
Model Evaluation by Echocardiography
and Hemodynamic Measurements
Twenty-eight days after surgery, echocardiography showed
down-regulation of EF and FS in AMI model group, with
46.68 and 61.67% decrease respectively as compared with Sham-
operated group. This was accompanied by increase in LVIDd
and LVIDs (53.14 and 147.49% increments, respectively), which
suggested cardiac hypertrophy in AMI development. After
treatment with QSYQ, EF, and FS were recovered by 28.53 and
37.20%, respectively. LVIDd and LVIDs of QSYQ-treated group
were recovered by 17.55 and 24.85%, respectively (Figure 1A and
Figure S2).
As shown in Figure 1B, in AMI model group, 2 indicators
reflecting LV systolic function—systolic blood pressure (SBP)
and Max dP/dt were reduced by 25.47 and 36.02% respectively,
compared to Sham-operated group. In QSYQ-treated group,
these indicators were significantly improved (5.8 and 33.61%
increments, respectively). Diastolic blood pressure (DBP)
and Min dP/dt, which were associated with LV diastolic
function, in AMI model group were decreased by 46.47 and
37.16% respectively, compared to Sham-operated group. QSYQ
treatment enhanced DBP and Min dP/dt by 63.78 and 30.41%
respectively. No difference was observed in heart rate among
3 groups. Echocardiography and hemodynamic measurements
demonstrated marked protective effects of QSYQ on improving
cardiac function and hemodynamics.
Global Therapeutic Effects of QSYQ on
AMI and Identification of Keystone
QSYQ-Regulated Genes
By comparison of AMI model with Sham-operated group,
868 DEGs were identified and regarded as AMI-pathogenic
genes, including 418 up-regulated and 450 down-regulated genes
(Figures S3A,D). The comparison of QSYQ-treated with AMI
model group revealed 2,733 DEGs (Figures S3B,D), consisting
of 1,344 up-regulated and 1,389 down-regulated genes. These
2,733 DEGs were considered as QSYQ-responsive genes. Out
of these 2 comparisons, 500 genes overlapped and showed
reverse differential expression, which were considered as QSYQ-
regulated genes. These genes included 221 inversely up-regulated
and 279 inversely down-regulated genes under QSYQ treatment
(Figures S3C,D). As shown in Figure S3C, QSYQ exerted a
significant modulation on global gene expression of AMI toward
the normal expression level, which accounting for therapeutic
effects of QSYQ on AMI. GCN was constructed with expression
profile of 500 QSYQ-regulated genes in 3 groups of samples.
PageRank (Brin and Page, 2012) further characterized the
centrality of genes in GCN. Targeted network attack analysis
(Figure S4) showed that the top 421 genes in PageRank ranking
were the hub genes of GCN. Thus, they were considered as the
“keystone QSYQ-regulated genes.”
A list of top 20 keystone QSYQ-regulated genes and their
biological functions are given in Table S1. It is intriguing to
note that most genes are related to extracellular matrix (ECM).
ECM abnormality is well known to be associated with VR,
which supports well relevance of our method for selection of
keystone QSYQ-regulated genes. Expression of these genes was
significantly up-regulated in AMI model compared with Sham-
operated group. Furthermore, their increased expression was
significantly reversed by QSYQ treatment.
Keystone QSYQ-regulated genes were mainly enriched in
cardiovascular diseases and cardiac signaling pathways, including
FIGURE 1 | The assessments of cardiac function by echocardiography and hemodynamics. (A) Echocardiographic analysis was performed in Sham, AMI,
and QSYQ (2.33 g/kg) groups for 28 days after LAD, n = 8 per group. (B) Hemodynamics analysis was carried out in each group. Data shown are the mean ± SD,
n = 9 per group. *P < 0.05; **P < 0.01; ***P < 0.001. #DBP and Min dP/dt are negative values.
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dilated cardiomyopathy, hypertrophic cardiomyopathy and
β-adrenergic receptor (β-AR)-mediated signaling pathway
(Figure S5).
Significance Analysis of Functional Group
Based on Keystone QSYQ-Regulated
Genes
Significance of functional groups was evaluated by our new
strategy based on priorities of keystone QSYQ-regulated
genes (Materials and Methods). Table S2 demonstrates
significance analysis for 15 functional groups. Significant
functional groups were identified with adjusted P <
0.005 (Group 1–6 in Table 1 and Figure 2). Some QSYQ-
responsive genes (not belong to functional groups), which
participate main KEGG pathways of significant functional
groups, were also included into analysis to help understand
therapeutic effects of QSYQ. Key genes of functional groups
and indicators of plasma lipid and lipoprotein levels were
validated and showed in Table 2, Table S3, and Figure 3.
Results of significant functional group analysis were shown as
follows.
QSYQ Suppressed Inflammatory Response
Induced by Arachidonic Acid LOX Pathway
(Group 1)
Inflammatory response induced by arachidonic acid
lipoxygenase (LOX) pathway was activated in AMI and
markedly suppressed by QSYQ treatment (Figure S6).
Expression of important genes in arachidonic acid LOX
pathway were significantly up-regulated in AMI process,
including arachidonate 15-lipoxygenase (ALOX15) and
matrix metallopeptidase 2 (MMP-2) (Table S3). After QSYQ
treatment, their expression was significantly decreased.
Western blot of ALOX15 and MMP-2 (Figures 3A,B)
further confirmed the regulatory effects of QSYQ
on suppression of arachidonic acid LOX pathway in
AMI.
QSYQ Enhanced NOS3 Expression and
Elevated NO Production (Group 6)
Production of nitric oxide (NO) from arginine metabolism
catalyzed by nitric oxide synthase 3 (NOS3) was markedly
increased after QSYQ treatment compared with AMI model
ones (Table S3), which was also observed by Western blot
(Figure 3B). Western blot also showed decreased expression
of NOS3 in AMI model compared with Sham-operated
group.
QSYQ Ameliorated Dyslipidaemia via
Up-Regulating Fatty Acid Oxidation
(Group 3)
Blood biochemical analyses were performed to evaluate plasma
lipid levels. Compared with Sham-operated, levels of TC, TG,
and LDL in AMI model group increased by 72.76, 306.25,
and 140.00%, respectively. HDL level decreased by 35.70%
in AMI model compared with Sham-operated group. After
treatment with QSYQ, levels of TC, TG and LDL decreased by
35.46, 46.15, and 84.37% respectively, as compared with model
group. HDL level was up-regulated by 28.49%. These findings
suggested that QSYQ ameliorated dyslipidaemia in rats with AMI
(Table 2).
As an important pathway to remove lipids from heart,
fatty acids oxidation was significantly inhibited in AMI and
reversely up-regulated after QSYQ treatment (Figure S7). The
affected genes included lipoprotein lipase (LPL), cluster of
differentiation 36 (CD36), acyl-CoA synthetase long-chain family
member 1 (ACSL1) and carnitine palmitoyltransferase 2 (CPT2)
(Table S3). Western blot confirmed significant reverse expression
changes of 3 key enzyme genes: LPL, CD36, and CPT2
(Figure 3C).
QSYQ Inhibited Cardiac VR (Top Keystone
QSYQ-Regulated Genes and Group 4)
A large proportion of top keystone QSYQ-regulated genes are
related with ECM. Of note, abnormal elevated expression of these
ECM-related genes was effectively inhibited by QSYQ treatment.
These ECM-related genes include transforming growth factor
beta 1 induced transcript 1 (TGFB1I1) and lipopolysaccharide-
induced TNF factor (LITAF) (Table S3). ECM abnormality
is regarded as a hallmark of VR. Moreover, in functional
group 4, it was also revealed inverse expression alterations in
ECM genes induced by QSYQ treatment (Figure S8), including
collagen type III alpha 1 (COL3A1) and collagen type V alpha
2 (COL5A2) (Table S3). IHC was applied to confirm the
inverse alterations of COL3A1 and COL5A2 (Figure 3D), which
supported the regulatory effects of QSYQ to ameliorate VR
in AMI.
TABLE 1 | Significant functional groups.
Number of groups* Enrichment score (ES) P-value Adjusted P-value Involved KEGG pathways
Group 1 4.162 <0.0001 <0.0001 Glutathione metabolism, Arachidonic acid metabolism
Group 2 3.528 <0.0001 <0.0001 Pyruvate metabolism, Citrate cycle (TCA cycle)
Group 3 3.093 <0.0001 <0.0001 Valine, leucine and isoleucine degradation, Fatty acid degradation
Group 4 2.886 <0.0001 <0.0001 Focal adhesion, ECM-receptor interaction
Group 5 2.397 <0.0001 <0.0001 Pentose phosphate pathway, Glycolysis/Gluconeogenesis
Group 6 1.601 0.0002 0.0020 Arginine and proline metabolism, Alanine, aspartate and glutamate metabolism
*Significant functional groups are ordered by ES decreasingly.
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FIGURE 2 | Significant functional groups. Genes are represented as nodes in the network and Entrez IDs are marked in the circle. The legend text denotes main
KEGG pathways and the number in bracket denotes count of genes in functional group.
QSYQ Accelerated BCAAs Degradation
and Other Energy Metabolism (Analyses of
Group 2, 3, and 5)
Up-regulation of branched-chain amino acids (BCAAs)
degradation by QSYQ treatment was identified in our study
(Figure S9). BCAA homeostasis is controlled by mitochondrial
branched-chain alpha-keto acid dehydrogenase complex
(BCKDC). 4 genes (BCKDHA, BCKDHB, DBT, and DLD)
encoding the catalytic subunits of BCKDC, were suppressed
in AMI model rats compared with Sham-operated ones (Table
S3). After QSYQ treatment, 2 of them were significantly
up-regulated: BCKDHA and DBT, which were confirmed by
Western blot (Figure 3E). The regulatory effects of QSYQ on
BCAAs degradation may mediate cardiovascular contractility
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TABLE 2 | Indicators of plasma lipid and lipoprotein levels in different
groups.
Group TC(mmol/L) TG(mmol/L) HDL(mmol/L) LDL(mmol/L)
Sham 0.75 ± 0.136** 0.064 ± 0.023** 0.54 ± 0.191* 0.03 ± 0.010**
AMI 1.30 ± 0.355 0.26 ± 0.060 0.34 ± 0.076 0.064 ± 0.019
QSYQ 0.84 ± 0.057** 0.14 ± 0.059** 0.44 ± 0.086 0.01 ± 0.006**
Compared with AMI group, *P < 0.05; **P < 0.01. n = 6 per group.
and compliance (Details in figure notes of Figure S9). In addition,
other energy metabolism including glycolysis (PRKAB1 and
ALDOA), TCA cycle (SUCLG1 and SUCLA2) and creatine
metabolism (CKM and CrT) were also accelerated by the
treatment of QSYQ (Table S3).
DISCUSSION
Therapeutic Effects of QSYQ:
Anti-Inflammation, Ameliorate
Dyslipidemia, and VR Progression
QSYQ Attenuates Inflammation through Suppressing
Arachidonic Acid LOX Pathway and Elevating
Production of NO
Inflammation mediated by arachidonic acid (AA) metabolism
pathway plays a critical role in AMI progression (Levick
et al., 2007; Wang et al., 2014).Our study identified significant
reverse gene expression changes in AA metabolism, especially
in arachidonic acid LOX pathway (Figure S6). AA is a kind
of polyunsaturated fatty acids, which is metabolized by 3 types
of enzymes: lipoxygenase (LOX), cyclooxygenase (COX), and
cytochrome P-450 (CYP) (Funk, 2001; Moreno, 2009). As shown
in Figure S6, in the LOX-catalyzed sub-pathway, ALOX15 and
ALOX5 can form hydroperoxyeicosatetraenoic acids (HPETEs),
which are further converted to hydroxyeicosatetraenoic acids
(HETEs) by glutathione peroxidases. Previous studies have
shown that hypoxia increases the proinflammatory enzyme
ALOX15 in human carotid plaques (Magnusson et al., 2012).
Furthermore, ALOX15 induces production of the reactive
signaling molecule 15-HPETE, which is a peroxidised lipid.
Of note, increased levels of peroxidised lipids are tightly
connected with complex inflammatory diseases such as AMI
(Spiteller, 2006). ALOX15 also catalyzes production of HETE.
HETE enhances the adhesion of leukocytes to endothelium
by activating chemokine production, which is an early event
in development of AMI (Hedrick et al., 1999). Ye et al.
(2004) has reported that 5-HETE induced the expression of
MMP-2, which supports our results. It is noted that matrix
metalloproteinases (MMPs) are involved in the degradation of
matrix components and contribute to VR progression in AMI.
Thus, our results demonstrated that the enhanced expression
levels of ALOX15 and ALOX5, contribute to accumulation
of pro-inflammation effects by HPETEs and HETEs, and
further exacerbate VR progression induced by MMPs. On the
other hand, increased expression of ALOX5AP accelerates the
accumulation of LTA4 and thus enhances AMI. Interestingly,
QSYQ treatment effectively suppresses inflammation by down-
regulating the key genes including ALOX15 and ALOX5AP
in arachidonic acid LOX pathway, and finally inhibits VR
indicators, including MMP-2 and MMP-23.
Meanwhile, NO synthesized from L-arginine by NOS3 can
reduce inflammation and oxidative stress through inhibiting lipid
peroxidation and scavenging superoxide anion (Katakami et al.,
2014), and thus alleviates VR in AMI progression.
QSYQ Ameliorates Dyslipidaemia through Elevating
CD36-CPT2-LPL Fatty Acid Oxidation
Dyslipidaemia is closely associated with exacerbation of
AMI. Our study demonstrated that QSYQ ameliorates the
dyslipidaemia through elevating CD36-CPT2-LPL fatty acid
oxidation.
The initial step of fatty acid metabolism is hydrolysis of
TG. LPL is the major enzyme responsible for hydrolysis of TG.
Moreover, LPL activity is positively correlated with HDL levels
(Blades et al., 1993; Tornvall et al., 1995). As an AMI Risk
in Communities Study shown, increased AMI risk has strong
associations with TC, LDL-C, and TG; while decreased AMI
risk is closely related with HDL-C (Sharrett et al., 2001). It was
demonstrated in the study that QSYQ decreases plasma TC, TG,
and LDL levels and up-regulate LPL expression and plasma HDL
levels, which effectively ameliorated dyslipidaemia and decreased
AMI risk.
After hydrolysis of TG into fatty acids, the next step is
the transportation of fatty acids from extracellular environment
to cytoplasm. CD36 as a fatty acid translocase, binds and
transports long chain fatty acids. Previous study (Krzystolik et al.,
2015) has suggested protective effect of higher soluble CD36
in coronary artery disease patients. Meanwhile higher soluble
CD36 concentration is also associated with lower risk of LV
hypertrophy (Krzystolik et al., 2015). Thus, overexpression of
CD36 induced by QSYQ is associated with lower risk of LV
hypertrophy.
Once transported into cytoplasm, fatty acids participate in
β-oxidation in mitochondria. It is noted that ACSL1, CPT2,
and ACADM genes, which encode key enzymes of fatty acid
β-oxidation, were significantly suppressed in AMI progression
and reversely enhanced after QSYQ treatment. ACSL1 is highly
expressed in oxidative tissues like brown adipose tissue and heart
(Ellis et al., 2011). Activated fatty acid normally provide 60–90%
of the substrate used by the heart for energy, but when ACSL1
is absent, fatty acid oxidation decreases more than 90% (Ellis
et al., 2011). CPT2 together with carnitine palmitoyltransferase
1 (CPT1), controls the rate of long-chain acyl-CoA transporting
into mitochondria from cytoplasm.
QSYQ Alleviates VR Progression
VR markers were elevated in AMI progression. QSYQ treatment
suppressed expression of VR markers as our results shown. In
atherosclerotic lesions, levels of ECM components, particularly
fibrillar collagen such as COL3A1 and COL5A2, are elevated
(Tyagi, 1999), which were validated in our study. Furthermore,
we identifiedmain causes of VR, inflammation and dyslipidaemia
were both ameliorated by QSYQ treatment.
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FIGURE 3 | Experimental validations of key genes of significant functional groups. Data shown are the mean ± SD, *P < 0.05; **P < 0.01; ***P < 0.001.
(A) QSYQ decreased gene expression level of ALOX15. n =3 per group. (B) QSYQ decreased gene expression level of MMP-2 and increased that of NOS3. n = 3 per
group. (C) QSYQ increased cardiac CPT2, CD36 and LPL in rats with AMI. n = 3 per group. (D) QSYQ inhibited cardiac-generated collagens such as COL3A1 and
COL5A2. n = 6 per group. (E) QSYQ increased cardiac BCKDHA and DBT in rats with AMI. n = 3 per group.
Overview of Multipronged Therapeutic
Effects of QSYQ on AMI
Multipronged therapeutic effects of QSYQ were summarized
in Figure 4 and Table S4. VR caused by inflammation and
dyslipidaemia is considered as a progressive yet irreversible
process and the most major pathological manifestation of AMI
(Sharrett et al., 2001; Tabas and Glass, 2013). In present study,
VR markers, such as COL3A1, COL5A2, and MMP-2, were
elevated in AMI progression. QSYQ treatment alleviated VR
through counter-acting the aforementioned events. Furthermore,
novel therapeutic effects of QSYQ were proposed in our study.
QSYQ can inhibit inflammatory response by down-regulating
arachidonic acid LOX pathway and elevating production of
NO. Meanwhile, QSYQ can ameliorate dyslipidaemia through
elevating CD36-CPT2-LPL fatty acid oxidation. Improvement
of fatty acid metabolism effectively increases energy supply to
cardiac contractility and relaxation in AMI and thus evaluates
EF value. In summary, QSYQ concurrently alleviated VR
progression, attenuated inflammation induced by arachidonic
acid LOX pathway and NO production, and ameliorated
dyslipidaemia in the treatment of AMI, thus improved cardiac
function and hemodynamics. TCM has upheld the holistic
therapeutic philosophy for more than 2000 years. Many Chinese
herbal formulae are multi-targeting in the treatment of diseases.
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FIGURE 4 | Overview of multipronged therapeutic effects of QSYQ on AMI. Therapeutic effects of QSYQ are highlighted with blue in our study:
anti-inflammation, ameliorate dyslipidemia and VR progression. Molecules in the figure were drawn with ChemBioDraw Ultra 12.0.
Our observations here support a multi-targeting mechanism for
QSYQ in the treatment of AMI.
New Strategy–Keystone Gene-Based
Group Significance Analysis
Many traditional strategies for network group significance
analysis focus on topological properties. For instance, MCODE
algorithm evaluates group significance with a cluster score, to
emphasize densely connected clusters (groups). However, density
cannot reflect the degree to which the group is relevant with
regulatory effects of QSYQ in our study. Our strategy introduces
quantitative information (PageRank scores of keystone QSYQ-
regulated genes) to character the regulatory effects of QSYQwhen
analysing the significance of functional group. To some extent,
our strategy is a particular enrichment test method which is
analogous to Gene Set Enrichment Analysis (Subramanian et al.,
2005).
Most enrichment test methods adopt overlap statistics
(Berriz et al., 2003; Doniger et al., 2003; Zhong et al., 2004;
Subramanian et al., 2005), which only concern the count
of overlap between the important genes and genes of a
certain pathway or ontology term. However, they do not
take advantage of the priorities of important genes and give
equal weight to every gene. Compared with these enrichment
test methods, our strategy differs in two regards. First, it
underscores both the priorities and count of keystone genes
in functional group. When genes of a group mainly distribute
on the top of priority list of keystone genes, the term Phit
is larger and then ES is larger. Meanwhile, if there are
more keystone genes in the group, corresponding Pmiss is
smaller and then ES is larger. Second, our strategy assesses
the significance level of ES by Monte Carlo simulation that
sample genes from the background network. This process
preserves the enrichment degree of observed functional group
with QSYQ-responsive genes, and thus, provides an accurate null
distribution. Keystone gene-based group significance analysis has
a broad application in evaluation of group significance with
priorities of genes.
CONCLUSIONS
Based on comprehensive transcriptome analyses and
experimental validation, we identified therapeutic effects of
QSYQ on AMI at multiple biological levels, including gene
expression, pathways involved and functional group. We
concluded that QSYQ concurrently alleviated VR progression,
attenuated inflammation induced by arachidonic acid LOX
pathway and NO production, and ameliorated dyslipidaemia
in the treatment of AMI. Moreover, our study provided a new
strategy to analyse the significance of functional group based on
the priorities of keystone genes, which has a broad application in
pharmacological studies.
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